Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/3452762 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554181129404416 |
|---|---|
| author | Alessandro Parisi Alessio Cortellini Katia Cannita Melissa Bersanelli Corrado Ficorella |
| author_facet | Alessandro Parisi Alessio Cortellini Katia Cannita Melissa Bersanelli Corrado Ficorella |
| author_sort | Alessandro Parisi |
| collection | DOAJ |
| description | Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of PD-L1 inhibitors in this population. Here, we report the first case of a male patient with metastatic urothelial cell carcinoma and ESRD on dialysis, safely treated with atezolizumab. |
| format | Article |
| id | doaj-art-d249f7d230004d6da577b20a65c4efe1 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-d249f7d230004d6da577b20a65c4efe12025-02-03T05:52:16ZengWileyCase Reports in Oncological Medicine2090-67062090-67142019-01-01201910.1155/2019/34527623452762Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on DialysisAlessandro Parisi0Alessio Cortellini1Katia Cannita2Melissa Bersanelli3Corrado Ficorella4Medical Oncology, St. Salvatore Hospital, L’Aquila, ItalyMedical Oncology, St. Salvatore Hospital, L’Aquila, ItalyMedical Oncology, St. Salvatore Hospital, L’Aquila, ItalyMedical Oncology, University Hospital of Parma, Parma, ItalyMedical Oncology, St. Salvatore Hospital, L’Aquila, ItalyAnti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of PD-L1 inhibitors in this population. Here, we report the first case of a male patient with metastatic urothelial cell carcinoma and ESRD on dialysis, safely treated with atezolizumab.http://dx.doi.org/10.1155/2019/3452762 |
| spellingShingle | Alessandro Parisi Alessio Cortellini Katia Cannita Melissa Bersanelli Corrado Ficorella Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis Case Reports in Oncological Medicine |
| title | Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis |
| title_full | Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis |
| title_fullStr | Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis |
| title_full_unstemmed | Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis |
| title_short | Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis |
| title_sort | safe administration of anti pd l1 atezolizumab in a patient with metastatic urothelial cell carcinoma and end stage renal disease on dialysis |
| url | http://dx.doi.org/10.1155/2019/3452762 |
| work_keys_str_mv | AT alessandroparisi safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis AT alessiocortellini safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis AT katiacannita safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis AT melissabersanelli safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis AT corradoficorella safeadministrationofantipdl1atezolizumabinapatientwithmetastaticurothelialcellcarcinomaandendstagerenaldiseaseondialysis |